Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) EBIT (2020 - 2024)

Immuneering (IMRX) has 5 years of EBIT data on record, last reported at -$18.6 million in Q4 2024.

  • For Q4 2024, EBIT fell 13.84% year-over-year to -$18.6 million; the TTM value through Dec 2024 reached -$64.1 million, down 9.69%, while the annual FY2024 figure was -$64.1 million, 9.69% down from the prior year.
  • EBIT reached -$18.6 million in Q4 2024 per IMRX's latest filing, down from -$15.3 million in the prior quarter.
  • Across five years, EBIT topped out at -$3.6 million in Q2 2020 and bottomed at -$18.6 million in Q4 2024.
  • Average EBIT over 5 years is -$12.0 million, with a median of -$13.3 million recorded in 2022.
  • Peak YoY movement for EBIT: tumbled 121.56% in 2021, then fell 4.4% in 2024.
  • A 5-year view of EBIT shows it stood at -$4.4 million in 2020, then crashed by 152.62% to -$11.1 million in 2021, then dropped by 25.81% to -$14.0 million in 2022, then fell by 16.57% to -$16.3 million in 2023, then decreased by 13.84% to -$18.6 million in 2024.
  • Per Business Quant database, its latest 3 readings for EBIT were -$18.6 million in Q4 2024, -$15.3 million in Q3 2024, and -$14.9 million in Q2 2024.